Triple therapy inhalers are expected to account for 11.3% of the total market. The chronic obstructive pulmonary disease ...

Pressurized metered-dose inhalers (pMDIs) for COPD and asthma contribute to climate change, and countries are moving away from their use.

With Chronic Breathing Issues on the Rise, AirPhysio Emerges as a Breakthrough Drug-Free Device Helping Millions Naturally ...

Ohtuvayre is the first new inhaled COPD therapy approved in over two decades. COPD is a chronic inflammatory condition that ...

The global aerosol delivery devices market was valued at $31,463.9 million in 2019, and is projected to reach $46,728.7 million by 2027, registering a CAGR of 4.9% from 2020 to 2027. Rise in ...